Fig. 3From: Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancerKaplan-Meier Analysis of Progression-free Survival. The median PFS was 7.5 months (95% CI: 4.0 to 14.3) based on a blinded independent central review. Abbreviation: PFS = progression-free survivalBack to article page